On Mar. 17, 2020, Regeneron announced that its scientists had isolated hundreds of virus-neutralizing, fully human antibodies from the company’s VelocImmune mice, which have been genetically-modified to have a human immune system.  Regeneron also isolated antibodies from humans who have recovered from COVID-19, in order to maximize the pool of potentially potent antibodies. Regeneron previously developed a successful treatment for Ebola virus infection, which is currently under review by the U.S. Food and Drug Administration.

In order to meet the pressing public health need, Regeneron is applying its VelociMab^® technology to prepare manufacturing-ready cell lines as lead antibodies are selected, so that clinical-scale production can begin immediately. The company is working toward the goal of producing hundreds of thousands of prophylactic doses per month by the end of summer and hopes to have smaller quantities available for initial clinical testing at the beginning of the summer. The company is working with the U.S. Health & Human Services’ Biomedical Advanced Research and Defense Authority (BARDA) to increase capacity even further.

All coronaviruses have a single glycoprotein on the virus surface called the spike protein, which is the protein on the virus cell surface that binds to the host cell and is required for infectivity. Regeneron’s SARS-CoV-2 antibodies will target the spike protein in order to block its interaction with the host cell, and thus neutralize the virus.